IBS-D Research Study

Are you living with Irritable Bowel Syndrome with Persistent Diarrhea (IBS-D)?

If so, consider joining the Enviva study, an IBS clinical trial for people with IBS-D investigating a new potential irritable bowel syndrome treatment.

*Volunteers will receive study-related care, including the cost of the issued study drug, at no cost. Participants may receive compensation for their time and travel.

Phase 2 Clinical Research Study.

The goal of Enviva is to explore the effect of an investigational drug on the symptoms of irritable bowel syndrome with predominant diarrhea (IBS-D).

Researchers are studying how the investigational drug may help ease unpleasant symptoms, such as abdominal pain, bloating, and altered stool consistency.

Get Started

COMPLETE THE QUESTIONNAIRE

*As a IBS-D research study participant, all study-related care will be provided at no cost to you, including the study drug. Participants may receive compensation for their time and travel

"*" indicates required fields

Name*
Are you 18 years of age or older?*
Have you been diagnosed with Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D)?*
Have you had mushy and loose stools over the last 3 months?*
Have you experienced abdominal pain at least 1 day per week over the last 3 months associated with bowel movements, frequency of bowel movements, and/or change in stool appearance?*
Are you willing to complete a daily electronic diary (eDiary) on your phone?*
This field is for validation purposes and should be left unchanged.

More Research Studies Coming Soon

Screening for Colon Cancer

IBS-C

GERD

Menstrual Migraines

Diabetic Glucometer Device Study
(open to ALL ethnicities)

 


We will have more studies available. Click below to join the waiting list.

St. Charles Clinical Research

6034 Weldon Spring Parkway
Weldon Spring, Mo. 63304

General Inquiries

Pharmaceutical Study Experience

Abbott

Pfizer

SKK

SERES

Boston Scientific

Allergan

Merck

Biohaven

Techfield

Baxter

Furiex

Salix Pharmaceuticals

Covance

Cubist

Eli Lilly

GlaxoSmithKline

Galen

Iroko

Ironwood

Medicago

Medimmune

Novartis

Novavax

Noven Therapeutics

Seqirus USA

Teva USA

Vanda pharmaceuticals